H.R.4030 (Treatment Continuity Act of 2025) amends Section 509 of the Public Health Service Act to add serious mental illness alongside substance use disorder as a priority and to authorize the Secretary of Health and Human Services to address those needs through access to FDA‑approved long‑acting injectable (LAI) medications. The amendment explicitly groups LAI access with associated lab testing, supportive counseling, and provider training as authorized activities under that statutory program.
The bill also revises the program’s reporting cadence: HHS must send an outcomes report to Congress within one year of enactment and annually thereafter that includes completed or substantial progress toward treatment requirements “based on clinician assessment.” The changes apply to grants made under section 509 after the act’s enactment, creating a federal pathway to prioritize LAIs and related services at the grant level without prescribing payment or coverage rules.
At a Glance
What It Does
The bill revises 42 U.S.C. 290bb‑2 (Section 509) to add serious mental illness and to authorize HHS to address priority needs through FDA‑approved long‑acting injectable medications, lab testing, counseling, and training on LAI use integrated with clinical services. It also requires annual outcome reports to Congress based on clinician assessment.
Who It Affects
Programs and providers that receive or seek grants under Section 509, HHS components (likely SAMHSA) that administer the program, manufacturers and distributors of FDA‑approved LAI products, and training/clinical support organizations that deliver counseling and lab services tied to LAI administration.
Why It Matters
By elevating LAIs and serious mental illness within an existing federal priority‑funding statute, the bill steers grant resources and program design toward long‑acting pharmacologic options and workforce training—potentially changing how community behavioral health programs structure continuity of care for SUD and SMI patients.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The core change is surgical: Section 509 of the Public Health Service Act, which targets regional and national priority treatment needs for substance use disorder, now explicitly includes serious mental illness. The statute’s authorized activities are rewritten to enumerate three program elements: (1) access to Food and Drug Administration‑approved long‑acting injectable medications for people with SUD or serious mental illness, (2) laboratory testing and supportive counseling for those conditions, and (3) training on the clinical use of LAIs together with counseling and related services.
That trio frames LAIs as one component of integrated care rather than a standalone intervention.
Implementation responsibility sits with the Secretary of Health and Human Services. The bill does not create a new entitlement, specify funding levels, or change FDA authority; it changes what HHS may prioritize when it awards or administers grants under Section 509.
Practically, agencies administering the program will need to translate the statutory list into grant solicitations, eligible activities, allowable costs, and performance measures that reflect LAI access, lab work, counseling, and training.Reporting is tightened. The previous periodic reporting structure is replaced with a firm one‑year deadline for the first report and annual reporting thereafter.
The reports must cover outcomes of the program and include “completed or substantial progress toward treatment requirements based on clinician assessment,” which signals that clinician‑reported outcomes will play a formal role in federal oversight and in how success is measured. Finally, the bill contains a short applicability clause: the amendments apply only to grants made after enactment, so awards already issued before that date are not retroactively changed.
The Five Things You Need to Know
The bill amends 42 U.S.C. 290bb‑2 (Section 509) to add "serious mental illness" alongside "substance use disorder" as a statutory priority for the program.
Section 509’s list of authorized activities is replaced to specifically authorize access to FDA‑approved long‑acting injectable medications for individuals with SUD or serious mental illness.
The revised statute explicitly authorizes lab testing and supportive counseling as program activities tied to SUD and serious mental illness treatment.
The statute requires training on the use of long‑acting injectable medications "for the purposes described" (i.e.
treatment access), and specifies that training should occur in combination with associated clinical services such as counseling.
HHS must transmit to Congress an outcomes report not later than 1 year after enactment and annually thereafter, including "completed or substantial progress toward treatment requirements based on clinician assessment," and the amendments apply to grants made under Section 509 after enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the Act as the "Treatment Continuity Act of 2025." This is purely stylistic but is the reference name used elsewhere in the statute and the reporting clause.
Add serious mental illness to the statutory scope
The bill amends the section heading and the opening language of subsection (a) to add "serious mental illness" to the program’s statutory mandate. Practically, this widens the population that HHS may prioritize under Section 509 and requires future discretionary program materials to reflect both SUD and SMI in eligibility, objectives, and evaluation criteria.
Enumerated authorized activities: LAIs, labs, counseling, training
Paragraphs (1)–(3) of subsection (a) are deleted and replaced with three concrete authorized activities: (1) access to FDA‑approved long‑acting injectable medications for SUD and SMI; (2) lab testing and supportive counseling for those conditions; and (3) training on LAI use combined with clinical services such as counseling. This is a mechanical authorization—HHS gains explicit statutory authority to fund those activities under Section 509, but the bill does not specify funding levels, procurement rules, or how access is to be operationalized.
Technical edits to subsection headings and cross‑references
The subsection (b) heading is altered to include serious mental illness, and the bill inserts parallel language into paragraphs (1) and (2) to ensure internal consistency. These are drafting changes to align statutory language with the expanded scope rather than new programmatic directives.
Annual outcomes reporting and limited retroactivity
Subsections (d) and (e) are replaced and redesignated so that HHS must transmit an outcomes report within 1 year of enactment and annually thereafter. The report must include outcomes and completed or substantial progress toward treatment requirements "based on clinician assessment." The bill also contains an applicability clause: its amendments apply only to grants awarded under Section 509 after the enactment date, leaving pre‑existing grants unchanged.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People living with serious mental illness and substance use disorders — the statute explicitly makes LAI medications and related services eligible activities under a federal priority program, which can increase access to long‑acting pharmacologic options and coordinated supports for continuity of care.
- Community behavioral health providers that win Section 509 grants — they can propose and be funded for LAI procurement, lab services, counseling, and staff training, enabling integrated service models that some clinics could not afford previously.
- Manufacturers and distributors of FDA‑approved LAI medications — the bill creates an explicit federal pathway that increases institutional demand for LAIs in grant‑funded programs and may expand market opportunities tied to publicly funded treatment programs.
- Clinical training organizations and laboratory service providers — the statutory authorization for training and lab testing opens new revenue streams for organizations that develop LAI clinical curricula or provide monitoring and testing services.
- Regional or rural programs seeking continuity solutions — Section 509 focuses on regional and national significance, so programs that can demonstrate geographic treatment gaps may gain priority access to funds for LAI‑based continuity strategies.
Who Bears the Cost
- HHS (and SAMHSA operationally) — the agency will need to develop program guidance, grant solicitations, monitoring frameworks, and the annual outcome reports mandated by the bill, imposing administrative and staffing burdens if additional appropriations do not accompany the change.
- Grant applicants and recipient providers — programs will face compliance, reporting, training, storage, and logistics costs when adding LAIs, labs, and counseling services to their operations; smaller providers may need to invest in cold‑chain storage and clinician training.
- Federal budget/taxpayers — while the bill authorizes certain activities, it anticipates grant dollars will be used; absent an appropriation, Congress would need to allocate funds to expand Section 509 programming, increasing outlays if implemented at scale.
- State Medicaid programs and other payers (indirectly) — wider federal support for LAIs could shift utilization patterns toward more injectable treatments, producing downstream coverage, utilization, and cost‑management questions for state payers even though the bill does not mandate coverage changes.
- Laboratory service vendors and ancillary staff — increased demand for lab testing tied to LAIs will require capacity and may raise local costs for clinics arranging outsourced services.
Key Issues
The Core Tension
The central tension is between two legitimate goals: improving continuity of care by expanding federal support for long‑acting injectable medications and the practical and ethical limits of doing so without dedicated funding, standardized outcome measures, and safeguards. The statute empowers HHS to prioritize LAIs and clinician‑reported outcomes, but enacting that authority without parallel appropriations, payer alignment, and protections for patient choice risks uneven implementation and potential infringement on patient autonomy.
The bill is narrowly focused on authorization and reporting; it does not provide appropriations or change FDA, Medicaid, or prescribing law. That creates an implementation gap: HHS can prioritize LAIs in grant programs, but uptake will depend on funding availability, state payer policies, and clinical practice patterns.
Programs funded under Section 509 will have to decide how to balance purchasing relatively expensive LAI products against other allowable costs like counseling or case management.
The reporting requirement centers outcomes "based on clinician assessment," which raises measurement questions. Clinician assessment is a practical, clinical marker, but it is subjective and may vary across settings and specialties; the statute does not define which clinician instruments, thresholds, or standardized measures will count as evidence of "completed or substantial progress," leaving significant discretion to HHS.
Finally, expanding federal support for LAIs intersects with ethical and legal concerns: LAIs improve adherence and continuity for many patients but have a historical association with coercive practices in some settings, so program design will need explicit safeguards on consent, choice, and patient autonomy that the bill does not address.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.